Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Lakefront Biotherapeutics NV maintains a gross margin of 25.95%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -982.92%, while the net margin is 214.26%. These profitability ratios, combined with a Return on Equity (ROE) of 16.26%, provide a clear picture of how effectively LKFT converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LKFT competes directly with industry leaders such as VIR and GLUE. With a market capitalization of $1.85B, it holds a leading position in the sector. When comparing efficiency, LKFT's gross margin of 25.95% stands against VIR's N/A and GLUE's 100.00%. Such benchmarking helps identify whether Lakefront Biotherapeutics NV is trading at a premium or discount relative to its financial performance.
